• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: April 18-22


ICYMI, this week we had stories on DAXI's BLA resubmission approval, sexual dysfunction and atopic dermatitis, and more.

POLL: Have you watched our recent episodes on MWN?

NPs Granted Full Practice Authority in New York

New York becomes 25th state to grant nurse practitioners full practice authority.

Patients with Skin Diseases Show Increased Interest in Medical Cannabis

As innovation in dermatology continues, so do questions on the efficacy of cannabinoid use for psoriasis, among other skin diseases.

Determining the Incidence and Prevalence of Alopecia Areata

A multicenter investigation provides information on the prevalence and incidence of alopecia areata in children.

Greater EAT-V May Predict Adverse Cardiovascular Risk in Men with Severe Psoriasis

A recent study showed that men with psoriasis have larger EAT-V than those without the skin disease.

The Mainstream Patient: April 18

This week's edition of the Mainstream Patients features stories about the causes of eczema, botox for TMJ, and more.

Workers at Small Firms Face Higher Costs for Family Insurance Coverage

New government rule aims to address some of the cost disparity.

Perspectives: FDA Warning Against Renuvion/J-Plasma

In this video interview, Darren Smith, MD, comments on the Renuvion/J-Plasma device (Apyx Medical) receiving an FDA warning for dermal resurfacing or skin contraction. He dives into how the device may be causing these issues, how this affects patients, and more.

The Cutaneous Connection: Sleep Disturbances in Older Patients with AD

Jonathan Silverberg, MD, the associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, joins us to discuss a poster from the December 2021 RAD conference.

Legislation Targets Mental Health Effects of COVID-19

Lawmakers want to expand telehealth options for children, cognitive research.

Sexual Dysfunction and Atopic Dermatitis

Unlike other psychological comorbidities, sexual dysfunction is a little explored field within AD.

Pointers with Dr Portela: Treating Dandruff

In this week’s Pointers with Dr Portela, the 208SkinDoc lists the top 5 ingredients to look for when patients are choosing over the counter solutions.

Supermajority of physicians in United States work for health systems or corporations

Pandemic greatly accelerated consolidation, threatening the independent practice of medicine.

Starting Off the SDNP Conference

The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee.

Enrollment in ARRECTOR Pivotal Phase 3 Trial Completed

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

Discovery: Gene Mutation Signals Aggressive Melanoma

Scientists from Mount Sinai have reported that a mutation of the ARID2 gene may be a key factor in the risk of melanoma turning metastatic.

Emergent Applications for Platelet-Rich Plasma

A comprehensive review explored new uses of this popular technology in aesthetic and medical dermatology.

Study: Patient-Reported Effectiveness of OnabotulinumtoxinA for Lateral Canthal Lines

Chinese patients with moderate to severe crow’s feet lines reported high levels of satisfaction with onabotulinumtoxinA treatment, according to a recently published study.

Physicians Spend 4.5 Hours a Day on Electronic Health Records

Study compiles data, finds multiple specialties affected.

FDA Accepts BLA Resubmission for DAXI Injections

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.